Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10986486 | 0.87 | — | — | |
| SCHEMBL38441 | 0.83 | — | — | |
| SCHEMBL20609970 | 0.83 | TSHR (0.46) | TSHRTDP1 | |
| SCHEMBL17607595 | 0.78 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL43156 | 0.78 | — | — | |
| SCHEMBL43753 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL27649357 | 0.75 | — | — | |
| SCHEMBL17607371 | 0.75 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL633248 | 0.73 | — | — | |
| SCHEMBL7971234 | 0.73 | TSHR (0.47) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194371-B1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY SCIENCE TECH & RES (SG) | 2020-09-02 | — | — | EP | disclosed |
| CN-107108518-B | Antibacterial imidazolium compounds | 新加坡科技研究局 | 2020-08-11 | — | — | CN | disclosed |
| US-10570097-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-25 | — | — | US | disclosed |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-17 | — | — | US | disclosed |
| US-10160728-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-12-25 | — | — | US | disclosed |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-12 | — | — | US | disclosed |
| EP-3194371-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | Agency for Science, Technology and Research (SG) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016043660-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-24 | — | — | WO | disclosed |
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| WO-2012019772-A1 | METHOD FOR TREATING PROTOZOAN PARASITIC DISEASES | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D) (FR) | 2012-02-16 | — | — | WO | disclosed |
| US-7842706-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| EP-2208726-A1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | Takeda Pharmaceutical Company Limited (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-20090246232-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2009-10-01 | — | — | US | disclosed |
| US-7538125-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070203198-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-08-30 | — | — | US | disclosed |
| US-7144900-B2 | Insulin sensitivity enhancer such as 5 -[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione or salt and a statin; antidiabetic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| US-20050054685-A1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-03-10 | — | — | US | disclosed |
| CN-1088711-C | Cephem compounds and medicines containing the same | SHIONOGI PHARMACEUTICAL & CO L (JP) | 2002-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570097-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | TSHR 3989/4885TDP1 4399/4885 |
| US-20050054685-A1 | Pharmaceutical composition | GPR119, IAPP, INSR | TSHR 1868/4885TDP1 2516/4885 |
| US-10160728-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | TSHR 3989/4885TDP1 4399/4885 |
| US-20070203198-A1 | Pharmaceutical composition | GPR119, IAPP, INSR | TSHR 1868/4885TDP1 2516/4885 |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | TSHR 3989/4885TDP1 4399/4885 |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | TSHR 3989/4885TDP1 4399/4885 |
| US-20090246232-A1 | Pharmaceutical composition | GPR119, IAPP, INSR | TSHR 1868/4885TDP1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.